Linkedin Facebook Contact with Pharma Industrial India
 

Last edition

March-April, 2026
All magazines
Subscribe to our magazine
autodoc
 
Home › News › Regulation

Piramal Pharma Completes US FDA Inspection at Lexington Facility

Piramal Pharma Completes US FDA Inspection at Lexington Facility

Piramal Pharma has announced the closure of a US Food and Drug Administration (FDA) inspection at its manufacturing facility in Lexington, Kentucky.

The FDA has issued an Establishment Inspection Report (EIR) for the facility, with a classification of Voluntary Action Indicated (VAI). The receipt of the EIR confirms that the inspection process has been formally concluded.

The company stated that this update follows its earlier disclosure dated December 11, 2025 regarding the FDA inspection at the Lexington site.
Read more on:
Establishment Inspection Report FDA inspection closure FDA inspection Piramal Pharma Pharmaceutical manufacturing compliance Piramal Pharma FDA inspection Lexington Piramal Pharma Lexington facility Piramal Pharma Limited USFDA
More news about: regulation | Published by News Bureau | April - 13 - 2026

Last news about this category

India Pharma 2026: Policy Push and Innovation Fuel Pharmaceutical Industry Growth India Pharma 2026: Policy Push and Innovation Fuel Pharmaceutical Industry Growth
Emalex Secures US Patent for Ecopipam ODT Emalex Secures US Patent for Ecopipam ODT
European Medicines Agency Recommends Ending Use of Tecovirimat SIGA for Mpox Treatment European Medicines Agency Recommends Ending Use of Tecovirimat SIGA for Mpox Treatment
Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD
Ipsen Discontinues Tazverik for Certain Cancer Uses Ipsen Discontinues Tazverik for Certain Cancer Uses
XYRA Secures US Patent for Dose-Adjusted Budiodarone Therapy Targeting Atrial Fibrillation and Heart Failure Risk XYRA Secures US Patent for Dose-Adjusted Budiodarone Therapy Targeting Atrial Fibrillation and Heart Failure Risk
MHRA Approves Brensocatib as First Targeted Treatment for Non-Cystic Fibrosis Bronchiectasis in UK MHRA Approves Brensocatib as First Targeted Treatment for Non-Cystic Fibrosis Bronchiectasis in UK
CDSCO to Outsource GMP Audits and Add 1,500 Experts to Boost Scientific Oversight CDSCO to Outsource GMP Audits and Add 1,500 Experts to Boost Scientific Oversight
CDSCO Flags 240 Drug Samples as Not of Standard Quality in January 2026 CDSCO Flags 240 Drug Samples as Not of Standard Quality in January 2026
FDA Issues Complete Response Letter for Disc Medicine's Bitopertin in Rare Blood Disorder FDA Issues Complete Response Letter for Disc Medicine's Bitopertin in Rare Blood Disorder
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members

Privacy Policy | Cookies Policy